This issue of Rheumatology Nurse Practice will focus on some of the most recent data concerning best practices for the management of rheumatoid arthritis and offer a variety of helpful tools to help build providers’ confidence. We’ll also examine treatment guidelines, review validated online resources, and provide a roadmap for how this information can translate into clinical practice.
Linda Grinnell-Merrick, MS, NP-BC
University of Rochester Medical Center
Division of Allergy, Immunology, and Rheumatology
Carolyn Zic, MSN, FNP-BC
Comer Children’s Hospital
Laura P. Kimble, PhD, RN, FNP-C, CNE, FAHA, FAAN
This activity has been designed to meet the educational needs of nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.
After participating in the activity, learners should be better able to:
- Define the term “shared decision making” and explain its importance in the management of patients with rheumatoid arthritis (RA)
- Analyze published guideline recommendations regarding first- and second-line treatment of RA
- Differentiate between the terms “cycling” and “swapping” as it relates to adjusting therapy in patients with RA
- Determine when it may and may not be appropriate to taper disease-modifying anti-rheumatic therapy in patients with RA who reach set treatment targets
Accreditation and Credit Designation
The Rheumatology Nurses Society is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).
Participants will receive 2.75 hours of continuing nursing contact hours, including 2.0 pharmacotherapeutic contact hours, by completing the education, completing an online evaluation, receiving a post-test score of 70%.
According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Planners, reviewers, and faculty have disclosed no conflicts of interest related to the content of this education, with the exception of the following:
Linda Grinnell-Merrick, MS, NP-BC:
Consultant: Janssen, Novartis, Abbie, Sanofi, Pfizer, UCB
Speakers Bureau; Janssen, Amgen, Novartis, AbbVie, Sanofi
Carolyn Zic, MSN, FNP-BC:
Advisory Board: Mallinckrodt
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE contact hours for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.
Support for this activity has been made possible through educational grants from Pfizer, AbbVie, and Gilead
© 2021. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).